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I M M U N O T H E R A P Y  
Immunotherapy for neurodegeneration? 
The role of innate and adaptive immunity in neurodegeneration remains controversial 
By Yingjun Liu and Adriano Aguzzi 
Alzheimer’s disease (AD), Parkinson’s dis-
ease (PD), and prion diseases such as Creutz-
feldt-Jakob disease, attack different parts of 
the central nervous system (CNS) and elicit 
distinct symptoms – yet they share many bi-
ochemical and neuropathological features. 
These include formation of protein aggre-
gates in the affected brain regions and pro-
gressive activation of non-neuronal cells in 
the brain that play crucial roles in immune 
responses. The activation of immune cells in 
the CNS (“neuroinflammation”) is prominent 
in these diseases. However, it remains un-
clear whether boosting or suppressing the 
immune system, in the brain or in the periph-
ery, may attenuate neurodegeneration. In 
the case of extraneural prion infections, ge-
netic or pharmacological ablation of compo-
nents of the immune system, such as B cells 
and complement, can prevent disease (1). 
However, immunotherapies, which have 
been successful in treating certain types of 
cancer, have yet to reverse neurodegenera-
tion in any patients.  Therefore, the therapeu-
tic promise of this approach remains debata-
ble. 
Immunotherapy such as immune check-
point blockade, which enhances the systemic 
adaptive immune response, may have poten-
tial in combating neurodegeneration, espe-
cially in AD (2, 3). But recent studies have 
failed to observe any beneficial effects of im-
mune checkpoint blockade in mouse models 
of AD (4) and of prion diseases (5, 6), raising 
questions about the effectiveness of this ap-
proach. Conversely, findings from studying 
human genetics and experimental models 
suggest that innate immunity in the brain has 
pivotal roles in the pathogenesis of neuro-
degenerative diseases. Therefore, targeting 
the immune reactions inside the brain may 
have enormous potential for treating these 
devastating disorders – yet a clear therapeu-
tic path is amiss, and well-defined, validated 
targets are still in demand.    
The inhibition of immune checkpoint re-
ceptors, an approach to fight cancers through 
boosting the adaptive immune system, has 
revolutionized cancer medicine (and was 
awarded a Nobel Prize in 2018). Immune 
checkpoint inhibition is mainly achieved by 
systemically blocking the activity of negative 
regulators of T cell activation, such as pro-
grammed cell death 1 (PD1), cytotoxic T-
lymphocyte associated antigen 4 (CTLA4) 
and lymphocyte activation gene 3 (LAG3). 
The expression of these molecules, among 
others, establishes a state of immune sup-
pression called tolerance towards cells of the 
body, which underlies the failure of the im-
mune system to clear tumor cells (which are 
derived from cells of the body). Might sys-
temic immune suppression contribute to the 
inefficient clearance of pathological protein 
aggregates in neurodegenerative diseases? 
Indeed, treatment with PD1-specific anti-
bodies enhanced infiltration of peripheral 
myeloid cells into the CNS and reduced the 
amount of amyloid β (Aβ) plaques in the hip-
pocampus and cortex (two brain regions 
most affected in AD) in two transgenic 
mouse models of AD. Moreover, LAG3 was 
found to facilitate the cell-to-cell spread of α-
synuclein in a mouse model of PD (7).  
Although PD1-specific antibodies are not 
harmless and can trigger autoimmunity, re-
purposing them for treating AD – an untreat-
able condition – could be justified. However, 
another study has found no effect of anti-PD1 
antibody therapy on myeloid cell infiltration 
into the brain and Aβ load in these CNS re-
gions in three other AD mouse models (4).  
The brain Aβ load does not always corre-
late with cognitive performance, and the ma-
jor determinant of cognitive decline is loss of 
synapses. Therefore, functional recovery 
tests deserve a high priority when evaluating 
therapeutic interventions for neurodegener-
ative diseases. Encouragingly, the clearance 
of Aβ plaques was accompanied by recovery 
of cognitive performance in some of the anti-
PD1 antibody-treated mouse models of AD, 
although effects on synapse dynamics was 
not studied (2). In other AD mouse models 
however, the effects of anti-PD1 treatment 
on cognitive function was not investigated 
(4).  Hence, the molecular underpinnings of 
the functional recovery in the successfully 
treated AD mouse models are still somewhat 
nebulous (see the figure). 
Moreover, immune checkpoint blockade 
may affect cognition independently of plaque 
clearance. A plethora of immune modulators, 
including cytokines, complement compo-
nents, and histocompatibility proteins play 
vital roles in synapse formation, refinement, 
and excitability, as well as in structural and 
functional synaptic plasticity during devel-
opment and in the adult brain (8)  Treatment 
with anti-PD1 antibodies may induce the ex-
pression of these immune modulators  and 
their entry into the CNS (see the figure).  
Mouse models of AD poorly represent the 
human condition. Could immune checkpoint 
blockade still hold therapeutic value for neu-
rodegenerative diseases? Although there is 
limited data on how immunotherapy affects 
the human brain, anecdotal clinical reports 
yield little reason for optimism. In contrast to 
mouse models of AD, cognitive deterioration 
is frequent among patients undergoing can-
cer treatments, including immunotherapy. 
Even in preclinical animal tumor models, 
blocking the immune checkpoint receptor 
CTLA-4 (combined with radiotherapy) re-
duced tumor growth but resulted in cogni-
tive impairment (9). In principle, because im-
mune checkpoint blockade enhances the 
overall ability of the adaptive immune sys-
tem to target multiple disease-associated fac-
tors, one could explore its usefulness in neu-
rodegenerative diseases other than AD.  
In prion diseases, however, targeting the 
immune checkpoint molecules PD1 and 
LAG3 did not alter prion deposition and the 
course of disease (5, 6). Moreover, loss of 
PD1 did not induce myeloid mobilization to 
prion-infected brains (6). These results again 
suggest that PD1 inhibition may not suffice to 
promote the entry of peripheral myeloid 
cells into the CNS. Therefore, current evi-
dence does not encourage the direct testing 
of immune checkpoint blockade in patients 
affected by neurodegenerative diseases. 
However, the increasing adoption of immune 
checkpoint inhibition against a growing vari-
ety of common cancers will enable appropri-
ately powered investigations of the effects of 
immunotherapy on human brain functions. 
Similarly, patients are increasingly subjected 
to anti-cancer immunotherapy, and some of 
them are likely to develop neurodegenera-
tive diseases as they age. Analyzing the pro-
gression of disease in these patients, includ-
ing neuropathological assessments of 
autopsied brains, may provide much-needed 
answers to these critical questions. 
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In a parallel narrative, growing evidence 
suggests that targeting the innate arm of im-
munity inside the brain may hold more 
promise than targeting its adaptive arm 
through systemic immune checkpoint block-
ade. The biggest surprise delivered by ge-
nome-wide association studies of neuro-
degeneration is the correlation of 
neuroinflammatory genes in these diseases 
(10). Many biological processes can lead to 
the activation of astrocytes and microglia 
(non-neuronal cells in the brain), which in 
turn can be beneficial or deleterious. Hence, 
identifying specific pathways for interven-
tion is crucial for the success of therapies tar-
geting non-neuronal cell reactions in neuro-
degenerative diseases.  
Perhaps the most promising progress in 
this aspect is the discoveries of inflam-
masome activation in AD, PD, and other sim-
ilar diseases such as amyotrophic lateral 
sclerosis (11-13). Inflammasomes are large 
complexes that play key roles in the innate 
immune responses and in the maturation 
and secretion of proinflammatory cytokines, 
such as interleukin-1IL-. An inflam-
masome consists of a sensor molecule, such 
as NOD, LRR- and pyrin domain-containing 3 
(NLRP3), the adaptor protein apoptosis-as-
sociated speck-like protein containing CARD 
(ASC), and caspase-1, which together form a 
functional complex upon infection, tissue 
damage, or protein misfolding, such as Aβ 
pathologic aggregation.  
In the brains of patients affected by AD 
and PD, the inflammasome is strongly acti-
vated within reactive microglia (11, 12). The 
cascade of inflammasome activation in these 
cells leads to the generation of ASC “specks,” 
large assemblies of ASC protein that can self-
propagate (much like prions), driving the 
neurotoxic inflammatory response and ac-
celerating AD pathology by acting as seeds 
for further Aβ aggregation (11, 14). Genetic 
inhibition of inflammasome activity reduces not only the Aβ load, but also proinflamma-
tory cytokine production and cognitive im-
pairment in mouse models of AD (11). Simi-
larly, oral treatment with a small molecule 
inhibitor of NLRP3 inflammasome pre-
vented -synuclein pathology and dopamin-
ergic neurodegeneration in PD mouse mod-
els, resulting in improved motor function 
(12).  
Furthermore, several non-steroidal anti-
inflammatory drugs (NSAIDs) of the 
fenamate class are effective inhibitors of 
NLRP3 inflammasome activation (15). 
Treatment with fenamate NSAIDs restored 
the cognitive function in a mouse model of 
AD (15). These studies have laid a solid foun-
dation for the clinical translation of inflam-
masome inhibitors and repurposing 
fenamates to treat AD and potentially other 
forms of neurodegeneration. 
Although at first they may seem contra-
dictory, these findings point to neuroinflam-
mation as a driver of AD and possibly of other 
neurodegenerative conditions. These devel-
opments herald a paradigm shift, away from the “amyloid cascade” hypothesis, which 
posits that in neurodegenerative diseases, 
pathologies stems from protein aggregation. 
Although nearly all therapeutic attempts are 
still aimed at quenching protein aggregation, 
it is increasingly evident that aggregation is 
only a part of the story. How the pathological 
accumulation of aggregated proteins affects 
innate (and perhaps adaptive) immunity, 
and vice versa, will certainly be addressed by 
future studies. Identifying the receptor, 
adapter, and effector molecules involved in 
this crosstalk may represent the best path 
forward to identify therapies that are more 
effective than those hitherto tested.  
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